News

Natco Pharma shares legal update on Risdiplam patent; stock up 3%
The stock rose 2.95 per cent to hit a high of Rs 789. It was last seen trading 1.44 per cent up at Rs 777.45. At this price, ...
Business Line9d
Natco Pharma to price Risdiplam at ₹15,900
Natco Pharma has decided to price Risdiplam, indicated for the treatment of rare genetic disorder Spinal Muscular Atrophy (SMA), at₹15,900. In an update on the legal proceedings on the ...
moneycontrol.com9d
Natco Pharma aims to launch generic of Roche’s rare disease drug after favourable ruling in patent infringement case
Natco Pharma on April 8 said that the launch of its generic version of Roche Pharma's patented drug, Risdiplam, is contingent upon the successful outcome in a patent infringement case.
Scroll22d
HC allows Natco Pharma to make Swiss firm Roche’s spinal muscular atrophy drug in public interest
The Delhi High Court on Monday refused to allow a lawsuit filed by Swiss pharmaceutical company Roche that sought to restrain Indian drug maker Natco Pharma from manufacturing Risdiplam ...
The Hindu8d
Natco to price Risdiplam generic at ₹15,900
Drugmaker Natco Pharma on Tuesday said it intends to launch its generic version of spinal muscular atrophy drug Risdiplam only after and subject to successful clarity from the Appellate Bench of ...